This is Genenta

Genenta is a clinical-stage biotechnology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Intrinsic immunological resistance significantly reduces the effectiveness of most cancer treatments, including leading-edge technologies such as checkpoint inhibitors and CAR-T cell therapies.

Our delivery system takes advantage of a subset of tumor-associated macrophages called TEMs (Tie-2-expressing monocytes) which normally have an affinity for and travel to tumors. Our platform engineers TEMs to deliver an immunotherapeutic payload within tumors, where it can direct the natural immune responses towards malignant cells. Our leading product, Temferon™,  has progressed into Phase 1/2a clinical trials in glioblastoma and is poised to impact other hard-to-treat cancer types.

Our history

Genenta was co-founded by Ospedale Raffaele Hospital (OSR), Milan, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner in 2015 to develop first in class cell and gene therapies for cancer. We leverage the vast experience of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), a world leading cell and gene therapy research institution at the forefront of developing therapies for rare diseases and a joint venture between OSR and Telethon. We maintain strong links with SR-Tiget with a partnership that acts as a research engine for our pipeline.

Pin It on Pinterest